Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) CEO Ivor Royston sold 13,162 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $1.90, for a total value of $25,007.80. Following the completion of the transaction, the chief executive officer now directly owns 600,930 shares of the company’s stock, valued at approximately $1,141,767. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Ivor Royston also recently made the following trade(s):
- On Monday, February 28th, Ivor Royston sold 14,635 shares of Viracta Therapeutics stock. The shares were sold at an average price of $2.78, for a total value of $40,685.30.
Viracta Therapeutics stock opened at $2.15 on Friday. The stock has a market capitalization of $80.60 million, a price-to-earnings ratio of -1.73 and a beta of 2.44. Viracta Therapeutics, Inc. has a 52-week low of $1.82 and a 52-week high of $13.08. The stock’s 50 day moving average price is $3.15 and its two-hundred day moving average price is $3.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.28 and a current ratio of 12.28.
Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC bought a new position in Viracta Therapeutics during the 4th quarter valued at $266,000. Oppenheimer & Co. Inc. bought a new position in Viracta Therapeutics during the 3rd quarter valued at $305,000. Advisor Group Holdings Inc. bought a new position in Viracta Therapeutics during the 3rd quarter valued at $39,000. BlackRock Inc. lifted its stake in Viracta Therapeutics by 1.2% during the 3rd quarter. BlackRock Inc. now owns 2,085,048 shares of the company’s stock valued at $16,723,000 after acquiring an additional 23,877 shares in the last quarter. Finally, Jump Financial LLC bought a new position in Viracta Therapeutics during the 3rd quarter valued at $175,000. Hedge funds and other institutional investors own 56.29% of the company’s stock.
Several research analysts have recently issued reports on VIRX shares. Royal Bank of Canada started coverage on Viracta Therapeutics in a research note on Tuesday, February 1st. They issued an “outperform” rating and a $10.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Viracta Therapeutics in a research report on Thursday, May 12th. Finally, Zacks Investment Research raised shares of Viracta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 13th.
About Viracta Therapeutics (Get Rating)
Viracta Therapeutics, Inc, a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
- Get a free copy of the StockNews.com research report on Viracta Therapeutics (VIRX)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.